Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. bought 20,529 shares of Abrdn Life Sciences Investors stock in a transaction on Wednesday, April 24th. The stock was acquired at an average cost of $13.12 per share, with a total value of $269,340.48. Following the acquisition, the insider now owns 2,807,724 shares of the company’s stock, valued at approximately $36,837,338.88. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Saba Capital Management, L.P. also recently made the following trade(s):
- On Monday, April 22nd, Saba Capital Management, L.P. acquired 2,022 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $12.88 per share, with a total value of $26,043.36.
- On Thursday, April 18th, Saba Capital Management, L.P. bought 81,738 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average cost of $12.80 per share, with a total value of $1,046,246.40.
Abrdn Life Sciences Investors Price Performance
Shares of NYSE:HQL opened at $12.97 on Friday. The business’s 50 day simple moving average is $13.49 and its 200-day simple moving average is $13.10. Abrdn Life Sciences Investors has a 12 month low of $11.34 and a 12 month high of $14.37.
Abrdn Life Sciences Investors Increases Dividend
Institutional Trading of Abrdn Life Sciences Investors
Large investors have recently bought and sold shares of the company. Future Financial Wealth Managment LLC purchased a new stake in shares of Abrdn Life Sciences Investors in the 1st quarter worth about $27,000. Matisse Capital acquired a new position in Abrdn Life Sciences Investors during the fourth quarter worth about $135,000. Blue Bell Private Wealth Management LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 60.4% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company’s stock valued at $136,000 after purchasing an additional 3,811 shares in the last quarter. Eudaimonia Partners LLC acquired a new stake in shares of Abrdn Life Sciences Investors in the first quarter valued at approximately $142,000. Finally, International Assets Investment Management LLC grew its position in shares of Abrdn Life Sciences Investors by 3,424.5% in the fourth quarter. International Assets Investment Management LLC now owns 11,067 shares of the company’s stock valued at $149,000 after purchasing an additional 10,753 shares during the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.
About Abrdn Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
See Also
- Five stocks we like better than Abrdn Life Sciences Investors
- What to Know About Investing in Penny Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- Financial Services Stocks Investing
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Investing in the High PE Growth Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.